Could a sugar imposter stop seizures?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of epilepsy. For the purpose of inclusion, the seizure types include complex partial, simple partial motor, primary generalized tonic-clonic, secondary generalized tonic-clonic, tonic, clonic and atonic seizures, as well as simple partial and absence seizures. * Stable treatment regimen with no change in antiepileptic drugs or antiepileptic drug doses for 28 days prior to enrollment. * Women of childbearing potential must be using a standard method of birth control and agree not to become pregnant during the trial. Men must agree to not father a child during the trial. * BMI must be between 18 and 35. Exclusion Criteria: * Occurrence of non-epileptic psychogenic spells within 2 years prior to enrollment. * Current or past history of diabetes or any abnormality of glucose metabolism. * Use of glucocorticoids, hypoglycemic agents (e.g. metformin) or any drug that alters glucose levels. * Use of any drug that is expected to alter glucose absorption, metabolism or serum measurements. * Clinically significant psychiatric or medical disease. * Previous therapeutic use of 2DG. * Pregnant or nursing women. * Use of an investigational medication within 2 months prior to enrollment. * Supine systolic blood pressure \< 90 or \> 160 mm Hg or diastolic \> 90 mm Hg, or pulse \< 60 or \> 110 BPM. * Clinically significant abnormal 12-lead ECG. * Baseline prolongation of the QTc interval \> 450 msec. * Clinically significant abnormal result by speckle tracking echocardiography (STE). * Elevated ALT or AST more than 1.5 times upper reference limit. * Baseline fasting glucose \< 60 or \> 110. * History of status epilepticus within 6 months prior to enrollment. * Progressive structural brain lesion or illness likely to progress during the study.